Michael Schoenbaum1, Jason M Sutherland2,3, Andre Chappel4, Susan Azrin1, Amy B Goldstein1, Agnes Rupp1, Robert K Heinssen1. 1. Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Boulevard, MSC 9669, Bethesda, MD 20892. 2. Agency for Healthcare Research and Quality, Rockville, MD. 3. Centre for Health Services and Policy Research, University of British Columbia, Vancouver, British Columbia, Canada. 4. Office of the Assistant Secretary for Planning and Evaluation (ASPE), Department of Health and Human Services, Washington, DC.
Abstract
Objective: To assess 12-month mortality and patterns of outpatient and inpatient treatment among young people experiencing an incident episode of psychosis in the United States. Method: Prospective observational analysis of a population-based cohort of commercially insured individuals aged 16-30 receiving a first observed (index) diagnosis of psychosis in 2008-2009. Data come from the US Department of Health and Human Services' Multi-Payer Claims Database Pilot. Outcomes are all-cause mortality identified via the Social Security Administration's full Death Master File; and inpatient, outpatient, and psychopharmacologic treatment based on health insurance claims data. Outcomes are assessed for the year after the index diagnosis. Results: Twelve-month mortality after the index psychosis diagnosis was 1968 per 100000 under our most conservative assumptions, some 24 times greater than in the general US population aged 16-30; and up to 7372 per 100000, some 89 times the corresponding general population rate. In the year after index, 61% of the cohort filled no antipsychotic prescriptions and 41% received no individual psychotherapy. Nearly two-thirds (62%) of the cohort had at least one hospitalization and/or one emergency department visit during the initial year of care. Conclusions: The hugely elevated mortality observed here underscores that young people experiencing psychosis warrant intensive clinical attention-yet we found low rates of pharmacotherapy and limited use of psychosocial treatment. These patterns reinforce the importance of providing coordinated, proactive treatment for young people with psychosis in US community settings. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2017.
Objective: To assess 12-month mortality and patterns of outpatient and inpatient treatment among young people experiencing an incident episode of psychosis in the United States. Method: Prospective observational analysis of a population-based cohort of commercially insured individuals aged 16-30 receiving a first observed (index) diagnosis of psychosis in 2008-2009. Data come from the US Department of Health and Human Services' Multi-Payer Claims Database Pilot. Outcomes are all-cause mortality identified via the Social Security Administration's full Death Master File; and inpatient, outpatient, and psychopharmacologic treatment based on health insurance claims data. Outcomes are assessed for the year after the index diagnosis. Results: Twelve-month mortality after the index psychosis diagnosis was 1968 per 100000 under our most conservative assumptions, some 24 times greater than in the general US population aged 16-30; and up to 7372 per 100000, some 89 times the corresponding general population rate. In the year after index, 61% of the cohort filled no antipsychotic prescriptions and 41% received no individual psychotherapy. Nearly two-thirds (62%) of the cohort had at least one hospitalization and/or one emergency department visit during the initial year of care. Conclusions: The hugely elevated mortality observed here underscores that young people experiencing psychosis warrant intensive clinical attention-yet we found low rates of pharmacotherapy and limited use of psychosocial treatment. These patterns reinforce the importance of providing coordinated, proactive treatment for young people with psychosis in US community settings. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center 2017.
Authors: Kally Yuen; Susy M Harrigan; Andrew J Mackinnon; Meredith G Harris; Hok Pan Yuen; Lisa P Henry; Henry J Jackson; Helen Herrman; Patrick D McGorry Journal: Schizophr Res Date: 2014-08-20 Impact factor: 4.939
Authors: Michael Schoenbaum; Jürgen Unützer; Daniel McCaffrey; Naihua Duan; Cathy Sherbourne; Kenneth B Wells Journal: Health Serv Res Date: 2002-10 Impact factor: 3.402
Authors: Jo Robinson; Meredith Harris; Sue Cotton; Ally Hughes; Philippe Conus; Martin Lambert; Benno G Schimmelmann; Patrick McGorry Journal: Psychiatry Res Date: 2010-04-21 Impact factor: 3.222
Authors: Gregory E Simon; Christine Stewart; Enid M Hunkeler; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; David S Carrell Journal: Am J Psychiatry Date: 2018-01-24 Impact factor: 18.112
Authors: Susan H Busch; Ezra Golberstein; Howard H Goldman; Christine Loveridge; Robert E Drake; Ellen Meara Journal: Psychiatr Serv Date: 2019-09-04 Impact factor: 3.084
Authors: Joanne B Newbury; Louise Arseneault; Avshalom Caspi; Terrie E Moffitt; Candice L Odgers; Jessie R Baldwin; Helena M S Zavos; Helen L Fisher Journal: Dev Psychopathol Date: 2017-12
Authors: Emily Kline; Victoria Hendel; Michelle Friedman-Yakoobian; Raquelle I Mesholam-Gately; Ann Findeisen; Suzanna Zimmet; Joanne D Wojcik; Tracey L Petryshen; Tsung-Ung W Woo; Jill M Goldstein; Martha E Shenton; Matcheri S Keshavan; Robert W McCarley; Larry J Seidman Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2018-11-28 Impact factor: 4.328
Authors: Gregory E Simon; Christine Stewart; Bobbi Jo Yarborough; Frances Lynch; Karen J Coleman; Arne Beck; Belinda H Operskalski; Robert B Penfold; Enid M Hunkeler Journal: JAMA Psychiatry Date: 2018-03-01 Impact factor: 21.596
Authors: Els van der Ven; Jennifer Scodes; Cale Basaraba; Luca Pauselli; Franco Mascayano; Ilana Nossel; Iruma Bello; Jennifer Humensky; Ezra Susser; Melanie Wall; Lisa Dixon Journal: Schizophr Res Date: 2020-06-05 Impact factor: 4.939